{"disease":{"id":"indolent-b-cell-lymphoma","name":"Indolent B-Cell Lymphoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"bendamustine","indication_name":"Indolent B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treanda","generic_name":"BENDAMUSTINE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Alkylating Drug","quality_score":63,"revenue":null,"mechanism":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"bendamustin","indication_name":"Indolent B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bendamustin","company_name":"Meir Medical Center","drug_phase":"marketed","molecular_target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03984448","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":363,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01994382","title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02362035","title":"ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Acerta Pharma BV","has_results":true},{"nct_id":"NCT03571568","title":"A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT06238648","title":"Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT06386315","title":"Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06343935","title":"A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":88,"lead_sponsor_name":"Shanghai YingLi Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT04703686","title":"Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"The Lymphoma Academic Research Organisation","has_results":false},{"nct_id":"NCT04533581","title":"Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT05418088","title":"Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Sumithira Vasu","has_results":false},{"nct_id":"NCT02494700","title":"Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05025800","title":"ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":47,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02384954","title":"QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":43,"lead_sponsor_name":"Altor BioScience","has_results":true},{"nct_id":"NCT07365306","title":"Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":43,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05169658","title":"Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06860880","title":"Combating Cancer-Related Fatigue: A Personalized Supportive Care Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03019666","title":"Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT05672251","title":"Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07098364","title":"ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06015880","title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03749018","title":"Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"David Bond, MD","has_results":false},{"nct_id":"NCT05583149","title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Patrick C. Johnson, MD","has_results":true},{"nct_id":"NCT06784726","title":"Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05359211","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03019640","title":"Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04806035","title":"Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05755087","title":"Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Lapo Alinari","has_results":false},{"nct_id":"NCT06209619","title":"CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Nathan Denlinger","has_results":false},{"nct_id":"NCT03133221","title":"1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":true},{"nct_id":"NCT03985189","title":"Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT03035331","title":"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03498612","title":"Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT04578600","title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Joseph Tuscano","has_results":false},{"nct_id":"NCT02846935","title":"p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Yogen Saunthararajah","has_results":false},{"nct_id":"NCT02483000","title":"Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02928510","title":"Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma","phase":"","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false}],"total":38},"guidelines":[],"source":"Drug Landscape verified database"}